EDITORIAL
1203  Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
   Alam S, Fahim SM

OPINION REVIEW
1208  Non-invasive real-time assessment of hepatic macrovesicular steatosis in liver donors: Hypothesis, design and proof-of-concept study
   Rajamani AS, Rammohan A, Sai VR, Rela M

REVIEW
1215  Impact of COVID-19 pandemic on liver, liver diseases, and liver transplantation programs in intensive care units
   Omar AS, Kaddoura R, Orabi B, Hanoura S

1234  In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?
   Echeverria N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J

1269  Pediatric non-cirrhotic portal hypertension: Endoscopic outcome and perspectives from developing nations
   Sarma MS, Seetharaman J

MINIREVIEWS
1289  Acute-on-chronic liver failure in children
   Islek A, Tunogor G

1299  Coronavirus disease 2019 in liver transplant patients: Clinical and therapeutic aspects
   Loinaz-Segurola C, Marcacuzco-Quinto A, Fernández-Ruiz M

1316  Pediatric vascular tumors of the liver: Review from the pathologist’s point of view
   Cordier F, Hooeens A, Van Dorpe J, Creytens D

1328  Autoimmune hepatitis in genetic syndromes: A literature review
   Capra AP, Chiara E, Bringlia S

1341  Assessing the prognosis of cirrhotic patients in the intensive care unit: What we know and what we need to know better
   da Silveira F, Soares PHR, Marchesan LQ, da Fonseca RSA, Nedel WL

1351  Liver transplantation for pediatric inherited metabolic liver diseases
   Vimalesvaran S, Dhawan A
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1367</td>
<td>Liver and COVID-19: From care of patients with liver diseases to liver injury</td>
<td>Gaspar R, Castelo Branco C, Macedo G</td>
</tr>
<tr>
<td>1378</td>
<td>Direct modulation of hepatocyte hepcidin signaling by iron</td>
<td>Yu LN, Wang SJ, Chen C, Rausch V, Elshaarawy O, Mueller S</td>
</tr>
<tr>
<td>1417</td>
<td>Machine learning models for predicting non-alcoholic fatty liver disease in the general United States population: NHANES database</td>
<td>Atsawarungruangkit A, Laoveeravat P, Promrat K</td>
</tr>
<tr>
<td>1450</td>
<td>Focal nodular hyperplasia associated with a giant hepatocellular adenoma: A case report and review of literature</td>
<td>Gaspar-Figueiredo S, Kefleyesus A, Sempoux C, Uldry E, Halkic N</td>
</tr>
</tbody>
</table>
ABOUT COVER
Editorial Board Member of *World Journal of Hepatology*, Julio Coelho, MD, PhD, Professor, Department of Surgery, Federal University of Parana, Curitiba 80240-110, Parana, Brazil. coelhojcu@yahoo.com.br

AIMS AND SCOPE
The primary aim of *World Journal of Hepatology* (WJH, *World J Hepatol*) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING
The WJH is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database. The 2021 edition of Journal Citation Reports® cites the 2020 Journal Citation Indicator (JCI) for WJH as 0.61. The WJH’s CiteScore for 2020 is 5.6 and Scopus CiteScore rank 2020: Hepatology is 24/62.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Xu Guo; Production Department Director: Xiang Li; Editorial Office Director: Xiang Li.

NAME OF JOURNAL
*World Journal of Hepatology*

ISSN
ISSN 1948-5182 (online)

LAUNCH DATE
October 31, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Nikolaos Pyrsopoulos, Ke-Qin Hu, Koo Jeong Kang

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
October 27, 2021

COPYRIGHT
© 2021 Baishideng Publishing Group Inc
Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease

Shahinul Alam, Shah Mohammad Fahim

ORCID number: Shahinul Alam 0000-0001-8053-0738; Shah Mohammad Fahim 0000-0002-3627-202X.

Author contributions: Alam S and Fahim SM contributed to this paper; Alam S designed the overall concept and outline of the manuscript; Fahim SM contributed to the discussion and design of the manuscript; Alam S and Fahim SM contributed to the writing, and editing the manuscript, and review of literature.

Conflict-of-interest statement: The authors declare that they have no competing interests.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Shahinul Alam, Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka 1000, Bangladesh
Shah Mohammad Fahim, Nutrition and Clinical Services Division, icddr, b, Dhaka 1212, Bangladesh
Corresponding author: Shahinul Alam, FCPS, MBBS, MD, Professor, Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka 1000, Bangladesh. shahinul@bsmmu.edu.bd

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern owing to its substantial contribution to chronic liver diseases. The disease is closely linked to metabolic syndrome (MS), suggesting a common biological pathway and shared disease mechanism for both ailments. Previous studies revealed a close relationship of NAFLD with the components of MS including abdominal obesity, dyslipidemia, hypertension, and hyperglycemia. Hence, a group of experts recently renamed NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD) in order to encompass a more appropriate pathogenesis of the disease. NAFLD was first named to describe a condition similar to alcoholic hepatitis in absence of significant alcohol consumption. However, knowledge pertaining to the etiopathogenesis of the disease has evolved over the past four decades. Recent evidence endorses NAFLD as a terminology of exclusion and suggests that it may often leads to misdiagnosis or inappropriate management of patients, particularly in clinical practice. On the other hand, the new definition is useful in addressing hepatic steatosis with metabolic dysfunction, which ultimately covers most of the patients with such illness. Therefore, it seems to be helpful in improving clinical diagnosis and managing high-risk patients with fatty liver disease. However, it is imperative to validate the new terminology at the population level to ensure a holistic approach to reduce the global burden of this heterogeneous disease condition.

Key Words: Nonalcoholic fatty liver disease; Metabolic dysfunction-associated fatty liver disease; Redefining; Redefinition of fatty liver disease

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
The rising burden of nonalcoholic fatty liver disease (NAFLD) is a global public health concern. This progressive liver disease is a leading cause of chronic hepatic ailments worldwide[1,2]. Recent reports confirm that NAFLD accounts for approximately 8% of the annual 2.14 million global deaths from liver disease[3]. Over the past two decades a substantial elevation in the prevalence of NAFLD has been reported, with strong evidence of a close link between NAFLD and metabolic syndrome (MS)[4]. NAFLD is often found to be associated with the components of MS, such as abdominal obesity, dyslipidemia, hypertension, and hyperglycemia[5]. In addition, the risk factors of NAFLD and MS have also been found to be identical in many studies[1]. Therefore, it has been suggested that both NAFLD and MS follow a common biological pathway as well as a shared disease mechanism. In line with that, a consensus of experts recently renamed NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD) so that the term could accurately reflect the pathogenesis of the disease[6]. According to the new definition, MAFLD would be diagnosed if there was evidence of hepatic steatosis in addition to any of the following three conditions, overweight/obesity, type 2 diabetes mellitus, or metabolic dysregulation[7]. The expert opinion was that the new definition is superior for diagnosing NAFLD patients with severe liver injury. Moreover, it is more practical to diagnose high-risk patients and evaluate disease progression in clinical settings[8,9].

DISCUSSION

Nonalcoholic steatohepatitis (NASH) was first used nearly four decades ago to describe a condition that mimics alcoholic hepatitis in absence of significant alcohol consumption[10]. Initially, the pathology was found to be linked to obesity or obesity-associated disorders. Subsequently, the disease was renamed NAFLD, referring to the absence of any known etiology of liver disease. In the meantime, a detailed understanding of the etiopathogenesis of the disease has evolved as the link between NAFLD, insulin resistance, and other components of MS was explored. Molecular-level investigations explored the role of multiple genetic and cellular mechanisms in the pathogenesis of NAFLD[11]. Epidemiological studies also revealed a number of social, demographic, and clinical determinants responsible for development of NAFLD[12]. Results of the studies described NAFLD as a heterogeneous condition. However, the archaic NAFLD nomenclature, which is a terminology of exclusion, remained unchanged over the years. The inclusion of alcohol in the name and definition is also problematic. In real-life clinical practice, the features of NAFLD often overlap with the characteristics of patients who consume alcohol. Moreover, there is no accepted method to appropriately measure alcohol intake in clinical facilities. Hence, there remains a possibility of misdiagnosis or inappropriate management of patients. Considering the above context, there has been a proposal to change the name since the beginning of this century. As the disease was found to be closely associated with metabolic dysfunction and insulin resistance, the scientific community proposed several names related to metabolic dysfunction, for example, metabolic steatohepatitis, metabolic fatty liver disease, and metabolic-associated fatty liver[10]. Eventually, a consensus of global experts opted for MAFLD.
Table 1 Potential positive implications and challenges related to transition of nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease

<table>
<thead>
<tr>
<th>Positive implications</th>
<th>Challenges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Useful in overcoming the dichotomization of NASH and non-NASH in clinical practices</td>
<td>Obtain a global acceptance as some researchers consider the name change premature and inappropriate</td>
</tr>
<tr>
<td>Facilitate diagnosis and evaluation of disease progression in high-risk patients</td>
<td>Underestimation of actual prevalence of the disease using the criteria of MAFLD</td>
</tr>
<tr>
<td>Improve awareness of physicians, healthcare providers and patients</td>
<td>Further clarification and stratification of the definition to guide decision-making and assess prognosis of the disease</td>
</tr>
<tr>
<td>Improve physician-patient communication</td>
<td>Address the patients with fatty changes in liver in absence of metabolic derangements</td>
</tr>
<tr>
<td>Improve clinical diagnosis and patient care</td>
<td>Deal with lean or undernourished individuals with hepatic fatty changes</td>
</tr>
<tr>
<td>Reduce confusion and stigma regarding the disease</td>
<td>Lack of information regarding genetic risk factors, phenotyping measurements, body fat content, and alterations in gut microbiota in the new definition</td>
</tr>
<tr>
<td>Increase public attention and improve health policy actions</td>
<td>Determine the outcome variable of ongoing clinical trials where “improvement in NASH” is one of the endpoints</td>
</tr>
</tbody>
</table>

MAFLD: Metabolic dysfunction-associated fatty liver disease; NASH: Nonalcoholic steatohepatitis.

It is assumed that the new definition would improve clinical diagnosis (Table 1). The term MAFLD annulled two different NAFLD entities, simple steatosis and NASH, and conceptualized the fatty changes in the liver as a disease process. Therefore, the redefinition of MAFLD would help to overcome the dichotomization of NASH and non-NASH, and facilitate the assessment of disease severity in clinical practice[13]. A recent study reported that the switch from NAFLD to MAFLD increased the awareness of physicians regarding the management of the disease[14]. However, changes in nomenclature may have potential implications for ongoing clinical trials in which “improvement in NASH” is an outcome variable. It is possible to redefine the outcomes of clinical trials based on the existing MAFLD framework, but there remains certain disagreement regarding the new terminology and its definition that need to be addressed[15]. The new criteria may underestimate the actual prevalence of the disease, as reported in a recent study[16]. It may also exclude patients without metabolic disturbances. A recent review found that metabolic derangements may be absent in 30% of the patients diagnosed with NAFLD[17]. The new definition is also not clear regarding concomitant liver diseases such as drug-induced, viral or auto-immune liver disease. Apart from individuals with high body mass index, NAFLD has also been reported in lean and nonobese adults. It is assumed that visceral adiposity and differences of metabolic adaptations may play a potential role in the pathogenesis of hepatic steatosis in lean adults[18]. Alterations in gut microbiota can also be a contributing factor in developing NAFLD in lean and undernourished adults[19]. Moreover, there is evidence in support of a significant relationship between a positive family history of metabolic traits and NAFLD, particularly in lean patients with a fatty liver[20]. Individuals with a family history of metabolic traits are likely to develop complications of NAFLD at a younger age[21]. Therefore, body fat content, rate of weight gain, and family history of metabolic traits need to be considered when constructing a new conceptual framework to define MAFLD. It seems that diagnosis of cryptogenic cirrhosis attributable to metabolic derangements would be easier using the new definition of MAFLD, as cryptogenic cirrhosis was found to be associated with obesity and diabetes[22]. Nevertheless, a more insightful opinion is required to establish an accurate definition so that the term incorporates individuals with hepatic fatty changes in the absence of metabolic derangements. Moreover, there should be definitive guidelines regarding inclusion of genetic risk factors, phenotypic measurements, dietary intake, visceral adiposity, and alterations in gut microbiota in the definition.

CONCLUSION

As more than one-fourth of the global population have NAFLD. Emphasis should be given to appropriate understanding of etiopathogenesis of the ailment[23]. To that end, an appropriate term is required so that it can reflect the entire pathophysiology of
the disease and cover the whole population with perturbed accumulation of hepatic fat. The new definition seems to address hepatic steatosis with metabolic dysfunction, which ultimately covers most of the cases with such illness. It is also useful for improving clinical diagnosis and managing high-risk patients with fatty changes in the liver. Therefore, the shift in terminology from NAFLD to MAFLD has already attained global endorsement. However, validation of the new term at the population level is warranted to ensure a holistic approach to reduce the global burden.

REFERENCES

11. Kuchay MS, Misra A. From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years. Diabetes Metab Syndr 2020; 14: 695-696 [PMID: 32442495 DOI: 10.1016/j.dsx.2020.05.019]
